Muhammad Umair Mushtaq (Abu Mikael)
@mumairmushtaq
Associate Professor Hematologic Malignancies & Cellular Therapeutics @KUMedCenter. Alumni @uwsmph @CookCountyIMR. All views are my own
ID: 3148931935
https://scholar.google.com/citations?user=CzpYfMYAAAAJ&hl=en 11-04-2015 02:37:17
535 Tweet
1,1K Takipçi
1,1K Takip Edilen
Congrats to Dr. Joseph McGuirk, recipient of Kansas City University’s Alumni Lifetime Achievement Award! A national leader in blood cancer & CAR T therapy, Dr. McGuirk has helped shape the future of oncology through decades of groundbreaking research & clinical innovation. Learn more:
Celebrating 35 years of academic excellence! The IFM has led groundbreaking trials shaping the modern era of high-dose therapy in myeloma. Proud to see this legacy highlighted in Blood Cancer Journal , showcasing how IFM research has set global standards for myeloma care.
CAR-T Outcomes in Post-Allo-Relapsed ALL review Moazzam Shahzad, MD Mikael Rayaan Foundation USMIRC News sciencedirect.com/science/articl…
AML-911: Incidence, Patterns, and Outcomes of Invasive Fungal Infections... Moazzam Shahzad, MD Mikael Rayaan Foundation USMIRC News sciencedirect.com/science/articl…
ABCL-905: Outcomes in Patients With Late Relapse of DLBCL... Moazzam Shahzad, MD Mikael Rayaan Foundation USMIRC News sciencedirect.com/science/articl…
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in R/R-MM ... USMIRC News sciencedirect.com/science/articl…
Shahzad M … Mushtaq MU. Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis. Leukemia & Lymphoma. 2025 Mikael Rayaan Foundation USMIRC News Moazzam Shahzad, MD doi.org/10.1080/104281…
In a seminal first-in-human study, we report durable remission in TP53-mutant AML post allo-HCT using donor-derived anti-CD33 CAR T (VCAR33)! This high-risk AML subset has had dismal outcomes—our results offer new hope. KU Cancer Center #AML #CART #Transplant #CancerResearch
Advancing Hematopoietic Cell Transplantation and Cellular Therapy Worldwide - Muhammad Umair Mushtaq Muhammad Umair Mushtaq (Abu Mikael) Mikael Rayaan Foundation KU Cancer Center KU Medical Center khalid A. Halahleh oncodaily.com/voices/muhamma… #Cancer #Medicine #Health #Oncology #OncoDaily #GlobalHealth #MedX #MedNews #MedEd
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals Al-Ola A Abdallah MD (USMIRC) USMIRC News mdpi.com/3575326 #mdpicancers
Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials mdpi.com/3600036 #mdpicancers via Cancers MDPI
Outcomes of CAR T-Cell therapy in relapsed/refractory multiple myeloma by race: a multicenter real-world study. Blood Cancer Journal. 2025; 15: 200 USMIRC News Al-Ola A Abdallah MD (USMIRC) KU Cancer Center nature.com/articles/s4140…
Outcomes after bone marrow versus peripheral blood haploidentical HCT KU Cancer Center USMIRC News Mikael Rayaan Foundation sciencedirect.com/science/articl…
Donor Age May Not Impact Post-Transplant Outcomes in MDS KU Cancer Center Mikael Rayaan Foundation USMIRC News rarediseaseadvisor.com/news/donor-age…
Pleased to welcome Dr. Mohammad Ma'koseh from KHCC Jordan to the KUMC Global Visitor Transplantation and Cellular Therapy Program! Together, we continue strengthening global expertise in transplantation and cell and gene therapies. Mikael Rayaan Foundation KU Cancer Center KU Medical Center
Welcoming Dr. Mohammad Ma’koseh to the KU Global Visitor Program - Muhammad Umair Mushtaq (Abu Mikael) KU Cancer Center oncodaily.com/voices/muhamma… #Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc CancerWorld
